Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: J Diabetes Complications. 2017 Jan 20;31(4):773–779. doi: 10.1016/j.jdiacomp.2016.12.010

Figure 2. Summary of the effects of raloxifene.

Figure 2

Raloxifene is an ER agonist in bone and acts as ER antagonist in breast. It has a neutral effect in uterus. Raloxifene reduced fat mass in OVX female rodents and prevented abdominal adiposity in postmenopausal women. Raloxifene’s effects on insulin sensitivity are controversial.